Cargando…
Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent kinase 4 and 6 inhibitors: large-scale data analysis using a Japanese claims database
PURPOSE: The aim was to understand real-world cyclin-dependent kinase (CDK) 4 and 6 inhibitor use in Japan. METHODS: This retrospective observational study used a Japanese administrative claims database and included patients with presumptive hormone receptor-positive, human epidermal growth factor r...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823084/ https://www.ncbi.nlm.nih.gov/pubmed/36414795 http://dx.doi.org/10.1007/s10549-022-06816-9 |
_version_ | 1784866078963269632 |
---|---|
author | Kawai, Masaaki Takada, Masahiro Nakayama, Takahiro Masuda, Norikazu Shiheido, Hirokazu Cai, Zhihong Huang, Yu-Jing Kawaguchi, Tsutomu Tanizawa, Yoshinori |
author_facet | Kawai, Masaaki Takada, Masahiro Nakayama, Takahiro Masuda, Norikazu Shiheido, Hirokazu Cai, Zhihong Huang, Yu-Jing Kawaguchi, Tsutomu Tanizawa, Yoshinori |
author_sort | Kawai, Masaaki |
collection | PubMed |
description | PURPOSE: The aim was to understand real-world cyclin-dependent kinase (CDK) 4 and 6 inhibitor use in Japan. METHODS: This retrospective observational study used a Japanese administrative claims database and included patients with presumptive hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (ABC) prescribed CDK4 and 6 inhibitor therapy between December 2017 and March 2021. Patient characteristics, treatment patterns, and selected clinical and safety outcomes were descriptively summarized. Time to discontinuation (TTD) and chemotherapy-free survival (CFS) were examined using Kaplan–Meier estimates. RESULTS: The study cohort (N = 6442) was predominantly female (99.4%; median [range] age 64 [26–99] years) with records of metastases (79.6%) within 1 year prior to initiating CDK4 and 6 inhibitor therapy. In total, 4463 (69.3%) and 1979 (30.7%) were prescribed palbociclib and abemaciclib, respectively, as their first CDK4 and 6 inhibitor, most commonly in combination with fulvestrant (n = 3801; 59.0%). Overall, 3756 patients initiated a subsequent anticancer treatment, of whom 748 (19.9%) initiated a different CDK4 and 6 inhibitor in combination with the same or different endocrine therapy. Median TTD (95% confidence interval) was 9.7 (9.3, 10.1) months for the first CDK4 and 6 inhibitor therapy. Median CFS was 26.1 (24.6, 27.8) months. Incidence of clinically relevant diarrhea was higher after abemaciclib initiation (9.8%) than after palbociclib initiation (1.5%). More patients experienced dose reduction with palbociclib (69.3%) than with abemaciclib (53.0%). CONCLUSION: The data provide insights into current clinical practices for CDK4 and 6 inhibitor use in Japan that could help establish future treatment strategies for ABC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10549-022-06816-9. |
format | Online Article Text |
id | pubmed-9823084 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-98230842023-01-08 Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent kinase 4 and 6 inhibitors: large-scale data analysis using a Japanese claims database Kawai, Masaaki Takada, Masahiro Nakayama, Takahiro Masuda, Norikazu Shiheido, Hirokazu Cai, Zhihong Huang, Yu-Jing Kawaguchi, Tsutomu Tanizawa, Yoshinori Breast Cancer Res Treat Epidemiology PURPOSE: The aim was to understand real-world cyclin-dependent kinase (CDK) 4 and 6 inhibitor use in Japan. METHODS: This retrospective observational study used a Japanese administrative claims database and included patients with presumptive hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (ABC) prescribed CDK4 and 6 inhibitor therapy between December 2017 and March 2021. Patient characteristics, treatment patterns, and selected clinical and safety outcomes were descriptively summarized. Time to discontinuation (TTD) and chemotherapy-free survival (CFS) were examined using Kaplan–Meier estimates. RESULTS: The study cohort (N = 6442) was predominantly female (99.4%; median [range] age 64 [26–99] years) with records of metastases (79.6%) within 1 year prior to initiating CDK4 and 6 inhibitor therapy. In total, 4463 (69.3%) and 1979 (30.7%) were prescribed palbociclib and abemaciclib, respectively, as their first CDK4 and 6 inhibitor, most commonly in combination with fulvestrant (n = 3801; 59.0%). Overall, 3756 patients initiated a subsequent anticancer treatment, of whom 748 (19.9%) initiated a different CDK4 and 6 inhibitor in combination with the same or different endocrine therapy. Median TTD (95% confidence interval) was 9.7 (9.3, 10.1) months for the first CDK4 and 6 inhibitor therapy. Median CFS was 26.1 (24.6, 27.8) months. Incidence of clinically relevant diarrhea was higher after abemaciclib initiation (9.8%) than after palbociclib initiation (1.5%). More patients experienced dose reduction with palbociclib (69.3%) than with abemaciclib (53.0%). CONCLUSION: The data provide insights into current clinical practices for CDK4 and 6 inhibitor use in Japan that could help establish future treatment strategies for ABC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10549-022-06816-9. Springer US 2022-11-21 2023 /pmc/articles/PMC9823084/ /pubmed/36414795 http://dx.doi.org/10.1007/s10549-022-06816-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Epidemiology Kawai, Masaaki Takada, Masahiro Nakayama, Takahiro Masuda, Norikazu Shiheido, Hirokazu Cai, Zhihong Huang, Yu-Jing Kawaguchi, Tsutomu Tanizawa, Yoshinori Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent kinase 4 and 6 inhibitors: large-scale data analysis using a Japanese claims database |
title | Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent kinase 4 and 6 inhibitors: large-scale data analysis using a Japanese claims database |
title_full | Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent kinase 4 and 6 inhibitors: large-scale data analysis using a Japanese claims database |
title_fullStr | Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent kinase 4 and 6 inhibitors: large-scale data analysis using a Japanese claims database |
title_full_unstemmed | Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent kinase 4 and 6 inhibitors: large-scale data analysis using a Japanese claims database |
title_short | Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent kinase 4 and 6 inhibitors: large-scale data analysis using a Japanese claims database |
title_sort | patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent kinase 4 and 6 inhibitors: large-scale data analysis using a japanese claims database |
topic | Epidemiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823084/ https://www.ncbi.nlm.nih.gov/pubmed/36414795 http://dx.doi.org/10.1007/s10549-022-06816-9 |
work_keys_str_mv | AT kawaimasaaki patientcharacteristicstreatmentpatternsandoutcomesofhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancerpatientsprescribedcyclindependentkinase4and6inhibitorslargescaledataanalysisusingajapaneseclaimsdatabase AT takadamasahiro patientcharacteristicstreatmentpatternsandoutcomesofhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancerpatientsprescribedcyclindependentkinase4and6inhibitorslargescaledataanalysisusingajapaneseclaimsdatabase AT nakayamatakahiro patientcharacteristicstreatmentpatternsandoutcomesofhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancerpatientsprescribedcyclindependentkinase4and6inhibitorslargescaledataanalysisusingajapaneseclaimsdatabase AT masudanorikazu patientcharacteristicstreatmentpatternsandoutcomesofhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancerpatientsprescribedcyclindependentkinase4and6inhibitorslargescaledataanalysisusingajapaneseclaimsdatabase AT shiheidohirokazu patientcharacteristicstreatmentpatternsandoutcomesofhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancerpatientsprescribedcyclindependentkinase4and6inhibitorslargescaledataanalysisusingajapaneseclaimsdatabase AT caizhihong patientcharacteristicstreatmentpatternsandoutcomesofhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancerpatientsprescribedcyclindependentkinase4and6inhibitorslargescaledataanalysisusingajapaneseclaimsdatabase AT huangyujing patientcharacteristicstreatmentpatternsandoutcomesofhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancerpatientsprescribedcyclindependentkinase4and6inhibitorslargescaledataanalysisusingajapaneseclaimsdatabase AT kawaguchitsutomu patientcharacteristicstreatmentpatternsandoutcomesofhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancerpatientsprescribedcyclindependentkinase4and6inhibitorslargescaledataanalysisusingajapaneseclaimsdatabase AT tanizawayoshinori patientcharacteristicstreatmentpatternsandoutcomesofhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancerpatientsprescribedcyclindependentkinase4and6inhibitorslargescaledataanalysisusingajapaneseclaimsdatabase |